Oak Brook, IL – Volume 36 of SLAS Technology includes two editorials, one literature highlight, two original research articles, two reviews and two Special Issue (SI) features.

Editorials

• Mass Spectrometry Applications for High-Throughput Experimentation in Supporting Drug Discovery
  High-throughput experimentation paired with mass spectrometry (MS) is accelerating drug discovery by enabling rapid, parallel analysis of thousands of chemical reactions and biological assays. While challenges such as data management and matrix effects remain, advances in MS technology, direct-to-biology workflows and AI integration are driving end-to-end optimization of the drug discovery process.
• 2^nd EUOS/SLAS Joint Challenge: Prediction of Spectral Properties of Compounds
  The Second Joint Machine Learning Challenge, built on the success of the first EU-OPENSCREEN/SLAS challenge, demonstrates how open, well-curated experimental datasets can accelerate the development of advanced machine learning methods for drug discovery. The editorial outlines the challenge–the full technical descriptions of the winning solutions will be published in SLAS Technology later this year.

Reviews

• Guide to Liquid Volume Measurements: A Review of Methods and Technologies
  This review surveys liquid volume measurement methods and technologies for life science laboratories, covering volumes from picoliters to milliliters across applications in biopharmaceutical and clinical settings. Key attributes evaluated include volume range, precision, accuracy, workflow integration and regulatory compliance.
• Toward Full Automation in Synthetic Biology: A Progressive Conceptual Framework Integrating Robotics and Intelligent Agents
  This article examines the role of robotics and AI in automating synthetic biology workflows, covering progress of physical and cognitive automation in synthetic biology. The authors propose a dual framework for both total automation of the full Design-Build-Test-Learn cycle and progressive automation that can be adapted to diverse laboratory contexts, while addressing the ethical considerations of increasingly autonomous biological research.

Original Research

• Implementation of a Modular Digital Laboratory Infrastructure for SiLA₂ Based Devices
  This article presents a laboratory digitalization framework using open-source software and hardware, demonstrated through a SiLA-based continuous chromatography system for Green Fluorescent Protein (GFP) purification. The framework includes device control, data management, evaluation, and maintenance strategies for software and hardware.
• Low-Cost CNC-Based Media Dispensing System for Biotechnology Laboratories
  A custom Computer Numerical Control-based Automated Media Dispensing System was developed and validated over two years for a plant biotechnology lab, outperforming manual dispensing while maintaining efficiency At approximately one-fiftieth the cost of comparable commercial systems, the modular design offers an accessible and ergonomic automation solution for research laboratories.

Literature Highlight

• Life Sciences and Aging
  This entry in the Life Sciences and Society series by SLAS Technology Associate Editor Kerstin Thurow, PhD, centers on advances in genomics, AI, and senolytic therapies that are giving life sciences increased power to intervene in the aging process, shifting the focus toward extending healthy lifespan rather than longevity alone.

Special Issues

• Robotics in Laboratory Automation
  This editorial introduces the Special Issue (SI) Robotics in Laboratory Automation, which highlights advances in robotic systems that improve experimental precision, reproducibility and throughput. The SI addresses key developments in standardization and intelligent automation while acknowledging current limitations and emerging trends shaping the field.
• Revolutionizing Transcriptomics from Single-Cell Insights to RNA-Based Interventions
  This SI on systems genetics examines gene and molecular interaction networks, utilizing high-throughput sequencing and multi-omics technologies to understand how genetic networks influence phenotypes. It emphasizes the significance of personalized medicine, therapeutic target discovery and biomarker identification through integrated genomic and epigenomic approaches.

All active SLAS Discovery and SLAS Technology call for papers are available at:

This volume of SLAS Technology is available at

*****

SLAS Technology reveals how scientists adapt technological advancements for life sciences exploration and experimentation in biomedical research and development. The journal emphasizes scientific and technical advances that enable and improve:

• Life sciences research and development
• Drug delivery
• Diagnostics
• Biomedical and molecular imaging
• Personalized and precision medicine

SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Technology: Translating Life Sciences Innovation, 2024 Impact Factor 3.7. Editor-in-Chief Edward Kai-Hua Chow, PhD, KYAN Technologies, Los Angeles, CA (USA).

###

Journal

SLAS TECHNOLOGY

The core of the investigation focuses on the structural intricacies of dibromodibenzoazepine derivatives, known for their vast biological applications. In this study, the authors leveraged advanced synthetic methodologies to design and create distinctive hybrid frameworks. This synthesis process was not merely a routine approach but a carefully calculated orchestration of chemical reactions aimed at optimizing biological activity while minimizing toxicity. By combining elements from diverse pharmacophores, the researchers aimed to innovate cancer therapeutics through structural finesse.

Characterization of the synthesized compounds formed a cornerstone of this research endeavor. Utilizing sophisticated techniques such as NMR (nuclear magnetic resonance) spectroscopy, mass spectrometry, and X-ray crystallography, the researchers meticulously examined the physicochemical properties of each distinct hybrid structure. These characterizations not only confirmed the successful synthesis of the novel compounds but also provided insights into their potential interactions within biological systems, setting the stage for deeper analysis into their efficacy.

A key element of this research was the utilization of computational analysis to predict how these compounds would behave at the molecular level. By employing molecular docking studies, the research team could visualize and anticipate how the novel dibromodibenzoazepine derivatives interact with critical cancer cell targets. Such computational methodologies are vital as they allow for the preliminary assessment of anticancer activity, reducing the time and resources spent on less promising compounds in the lab.

The study’s significance is amplified through its investigation of the structure-activity relationship (SAR) of these new hybrid derivatives. Understanding how various structural modifications impact biological activity forms the backbone of rational drug design. By elucidating these relationships, the researchers have paved the way for future investigations, potentially identifying the most effective configurations for treating specific types of cancer. Their findings suggest that even slight alterations in molecular structures can significantly impact the selective cytotoxic effects against cancer cells, underscoring the complexity and potential of organic chemistry in medicinal applications.

Beyond just theoretical insights, this research involved in vitro and in vivo assays to test the anticancer potential of the most promising compounds. The researchers meticulously designed these experiments to investigate how well these hybrids could inhibit cancer cell proliferation and induce apoptosis. The results were promising, demonstrating a marked reduction in tumor size in animal models, spurring excitement about the future applicability of these compounds in clinical settings.

Evidently, the battle against cancer is evolving, and this study contributes uniquely to the arsenal of chemotherapeutic strategies. By integrating multidisciplinary approaches—from synthetic chemistry to computational modeling—the authors illustrate a powerful paradigm shift in drug discovery that resonates with contemporary demands for specificity and efficacy in treatment protocols. The hybrid structures explored in this work promise not merely to add to the vast compendium of chemotherapy but to redefine the standards by which new agents are evaluated.

In the larger context of cancer research, collaboration among chemists, biologists, and computational scientists enhances the overall impact of such studies. The interdisciplinary nature of this work exemplifies how collective expertise can result in more nuanced understandings and solutions tailored to the multifaceted challenges posed by cancer. As this research moves toward clinical trials, the foundation it has laid will enable further study into these compounds’ implications and applications in real-world scenarios.

The journey from the laboratory to clinical application is fraught with challenges, yet the innovative mindset adopted by Allıto and colleagues exemplifies the promising future ahead for cancer therapies. Their exploration into dibromodibenzoazepine derivatives reflects a judicious blend of creativity and scientific rigor, driving the frontier of modern oncology toward novel, more effective treatment modalities. As researchers continue to refine these compounds, the ultimate goal remains clear: to transform cancer care, making it more effective and tailored to the needs of patients around the world.

To sum up, the revelations provided by Allıto, Onder, and Comert Onder mark a significant milestone in cancer research. Their work stands as a reminder of the intricate dance between chemistry, biology, and technology in the quest for improved cancer treatments. As we stand on the precipice of potentially transformative discoveries, one can only be optimistic about the future landscape of oncological therapy, where customized treatment strategies could become the norm rather than the exception.

In conclusion, the emergence of dibromodibenzoazepine-based hybrid structures as potential anticancer agents underscores not only the ingenuity of contemporary researchers but also the importance of continued innovation in the field of medical research. The findings from this comprehensive study promise to inspire future endeavors, inviting new perspectives and possibilities in the relentless fight against cancer.

Subject of Research: Anticancer potential of dibromodibenzoazepine-based hybrid structures.

Article Title: Design, synthesis, characterization, computational analysis, structure-activity relationship, and investigation of the anticancer potential of novel dibromodibenzoazepine-based hybrid structures.

Article References: Allıto, A., Onder, A., Comert Onder, F. et al. Design, synthesis, characterization, computational analysis, structure-activity relationship, and investigation of the anticancer potential of novel dibromodibenzoazepine-based hybrid structures. Mol Divers (2025). https://doi.org/10.1007/s11030-025-11418-w

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11030-025-11418-w

Keywords: Dibromodibenzoazepine, anticancer, hybrid structures, structure-activity relationship, drug design, synthetic chemistry, computational analysis.